Online adaptive radiotherapy for cervical cancer treatment
Official title: Online Adaptive Radiotherapy (oART) in Radical Radiotherapy for Cervical Cancer - A Multi-center Randomized Controlled Study
Run by Peking Union Medical College Hospital · NCT06562166 · Data updated 2026-11-12
This study tests if a new online adaptive radiotherapy can help women with cervical cancer get better results and experience fewer side effects compared to standard treatment.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 80 Years |
| Sex | Women only |
| Enrollment | 124 (estimated) |
| Sponsor | Peking Union Medical College Hospital Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Beijing) |
| Status | Recruiting |
| Started | September 5, 2024 |
| Main results expected | August 1, 2027 |
| Study ends | December 1, 2028 |
| Registry record updated | January 8, 2026 |
| Trial ID | NCT06562166 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18-70 with pathologically confirmed cervical squamous carcinoma at specific FIGO stages who are eligible for radical pelvic radiotherapy.
✕Probably not a fit
Patients with non-squamous types of cervical cancer or those not meeting the eligibility criteria may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study evaluates the clinical efficacy and safety of online adaptive radiotherapy in patients with cervical cancer undergoing radical radiotherapy. It compares this approach with traditional image-guided radiotherapy to assess potential benefits in reducing treatment toxicity and enhancing local control of the cancer. The trial includes patients aged 18-70 with confirmed cervical squamous carcinoma and specific FIGO stages, who will receive concurrent chemotherapy. The study aims to provide insights into the effectiveness of adaptive radiotherapy in improving patient outcomes.
Why it matters
Potential benefit: If successful, this approach could lead to reduced treatment side effects and improved cancer control for cervical cancer patients.
How similar studies have gone: Previous studies have shown promise in adaptive radiotherapy approaches, suggesting potential benefits, though this specific application may be novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. 18-80 years old; 2. Pathologically confirmed diagnosis of cervical cancer and pathological type of cervical squamous carcinoma; 3. 2018 FIGO Stage Ib3, II, IIIB and IIIC1 4. Proposed radical pelvic radiotherapy + concurrent sensitizing chemotherapy (platinum-based (cisplatin 30-40mg/m2 or carboplatin alone), starting concurrently in the first week, ≥5 courses) 5. ECOG score 0-2 6. Life expectancy greater than 6 months 7. Ability to remain lying down for more than 30 minutes 8. Patients were fully voluntary and autonomous and co-operated in signing the study informed consent form 9. Complete blood count and basal metabolic indexes within 14 days before enrolment must meet the following requirements: NEUT ≥ 1.5\*109/L, HGB ≥ 60g/L, platelets ≥ 100×109/, blood creatinine \<1.5 mg/dL. AST and ALT are within 2 times the upper limit of normal 10. Must complete baseline assessments and investigations required before treatment before enrolment 11. be eligible for regular follow-up Exclusion Criteria: 1. Have received radiotherapy or chemotherapy in the past 2. Have undergone radical surgery for cervical cancer 3. Have a previous history of malignant tumor 4. Pregnant or lactating women 5. Presence of other serious co-morbidities such as poorly controlled cardiovascular, urinary, digestive, respiratory, hematological and central nervous system diseases.
Where it's running
-
Peking union medical college hospital
Beijing, China Recruiting
Study contacts
- Study coordinator: Shuai Sun
- Email: sunshuai@pumch.cn
- Phone: 15801390180
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Cervical screening and care options for women living with HIV who test positive for high-risk HPV
This study tests different ways to screen and manage high-risk HPV in women with HIV to see what might work best for them.
-
Hydrogel spacer to protect the rectum during cervical cancer radiotherapy
This study tests whether placing an absorbable hydrogel spacer between the cervix/vagina and rectum before definitive radiotherapy can reduce rectal radiation exposure for women with cervical cancer.
-
How cinema sessions during chemotherapy might help cervical cancer patients
We’re testing if watching films during chemotherapy helps cervical cancer patients feel less anxious and improve quality of life.
-
One-Finger Technique to identify the left upper ureter during para-aortic lymphadenectomy
This study tests a new surgical method to help surgeons find the left upper ureter during open para-aortic lymphadenectomy in women with gynecologic cancers.
-
Radiotherapy for gynecologic cancer with up to 10 metastatic sites
This registry follows adults with gynecologic cancer who have 1 to 10 active metastatic lesions and are treated with radiotherapy as part of routine care to see how such treatments work in real-world settings.
-
Stellate ganglion block and dexmedetomidine for better sleep after gynecologic laparoscopy
The study tests whether giving a preoperative stellate ganglion block plus intraoperative dexmedetomidine improves sleep after laparoscopic gynecologic surgery in women.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.